Menu
Search
|

Menu

Close
X

Tyme Technologies Inc TYME.OQ (NASDAQ Stock Exchange Capital Market)

2.90 USD
+0.02 (+0.69%)
As of 8:24 PM BST
chart
Previous Close 2.88
Open 2.91
Volume 13,904
3m Avg Volume 85,260
Today’s High 2.94
Today’s Low 2.82
52 Week High 9.50
52 Week Low 2.01
Shares Outstanding (mil) 89.32
Market Capitalization (mil) 464.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.209
FY17
-0.176
FY16
-0.141
FY15
-0.155
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
54.21
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-215.09
14.61
Return on Equity (TTM)
vs sector
-215.09
16.34

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

17 State St Fl 7
NEW YORK   NY   10004-1585

Phone: +1646.2051603

Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.

SPONSORED STORIES